drugset / Trial / NCT00902200

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200

Phase 2 Completed 89 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.

Timeline

Start
2009-05
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject VEROSUDIL Small molecule 0.05 % Other
Subject VEROSUDIL Small molecule 0.1 % Other
Subject VEROSUDIL Small molecule 0.25 % Other

Indications